Cover Image

Gastrointestinal Stromal Tumor (GIST) Presenting As Acute Urinary Retention A Rare entity

NEELAKANDAN R

Abstract


In males Infra vesical obstruction can cause  urinary retention. This obstruction could be intrinsic or extrinsic. In Most of the cases benign prostatic hyperplasia is the commonest cause for urinary retention. But extrinsic  factors causing urinary retention are very rare. Intra or retroperitoneal mass lesion which compressing the bladder neck or posterior uretheral region may present as urinary retention. So non urological causes also born in mind when there is no urological evidence for obstruction.

 


Full Text:

PDF

References


Rosenstein D, McAninch JW. Urologic emergencies. Med Clin North Am. 2004;88(2):495–518.

Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virch Arch 2001;438:1–12.

Gervaz P, Huber O, Morel P. Surgical management of gastrointestinal stromal tumours. Br J Surg 2009;96:567– 78.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal

tumors. Science.1998;279:577–580. doi: 10.1126/science.279.5350.577. [PubMed] [Cross Ref]

Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, Füzesi L. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007;14:526–532. doi: 10.1245/s10434-006-9228-0. [PubMed] [Cross Ref]

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216. doi: 10.1093/jnci/92.3.205. [PubMed] [Cross Ref]

Eisenberg BL, Harris J, Blanke C, Demetri GD, Heinrich MC, Watson JC, et al. Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST)—early results of RTOG 0132. J Surg Oncol 2009;99:42 –7.

Dorfman DM, Bui MM, Tubbs RR, et al. : The CD 117 Immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study. Arch Pathol Lab Med 130:779–82, 2006 [PubMed]

Fletcher CD, Berman JJ, Corless C, et al. : Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 10:81–89, 2002 [PubMed]


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr MGR Medical University